This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 May 2012

Kythera Biopharmaceuticals Announces Plans to Go Public

Drug developer Kythera Biopharmaceuticals is to go public in a bid to generate funds for its ongoing clinical development of aesthetic medicine ATX-101.

Kythera Biopharmaceuticals has announced plans to go public after filing with the US Securities and Exchange Commission.


The clinical-stage biopharmaceutical developer - which discovers, develops and sells products for the aesthetic medicine market - has filed for an initial public offering (IPO) to raise up to $86.2 million in sales of common stock.


It has not announced the number of shares to be offered or the price range for the offering.


According to reports, Kythera will use most of the money generated from an IPO to fund phase-III clinical development of its lead product candidate ATX-101.


The injectabl

Related News